Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor

@article{Xue2013AntidepressantlikeEO,
  title={Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor},
  author={Rui Xue and Zeng Jin and Hong-xia Chen and Li Yuan and Xin-hua He and Yan-ping Zhang and Yong-gang Meng and Jiang-Ping Xu and Jian-quan Zheng and Bo-hua Zhong and Yun-feng Li and You-zhi Zhang},
  journal={European Neuropsychopharmacology},
  year={2013},
  volume={23},
  pages={728-741}
}
View on Elsevier
doi.org
47 Citations
Highly Influential Citations
1
Background Citations
6
Methods Citations
11
Results Citations
1

47 Citations

Citation Type

Citation Type

The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor
The discovery of 071031B, a novel serotonin and noradrenaline reuptake inhibitor
Antidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist
TLDR
It is suggested that YL-0919, a novel structure compound, exerts dual effect on the serotonergic system, as both 5-HT1A receptor agonist and 5- HT uptake blocker, showing remarkable antidepressant effects in animal models, and may be used as a new option for the treatment of major depressive disorder.
Effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor, on monoamine system in mice and rats.
Effects of 071031 B , a novel serotonin and norepinephrine reuptake inhibitor , on monoamine system in mice and rats
TLDR
The results revealed that 071031B produces potent inhibition of 5-HT and NE reuptake in vivo, without effect on DA and its metabolites.
Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors
TLDR
It is suggested that S-71031B is a more active enantiomer, and the differential pharmacokinetic profiles, but not target affinity, contribute to differences of S-071031 B and R-07 1031B in behavioral pharmacology.
Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist
Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor
TLDR
Ammoxetine effectively alleviates inflammatory, continuous, neuropathic and fibromyalgia-related pain in animal models, which can be attributed to enhanced neurotransmission of 5-HT and NE in the descending inhibitory systems.
Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression
TLDR
6z is a novel 5-HT3 receptor antagonist with potential antidepressant-like activities, which may be related to modulating hypothalamic-pituitary-adrenal axis and attenuating brain oxidative damage.
SNRIs achieve faster antidepressant effects than SSRIs by elevating the concentrations of dopamine in the forebrain
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties
TLDR
F-98214-TA is a novel SNRI that displays greater potency than other reference antidepressants in animal models predictive of antidepressant and anxiolytic activities and was more potent than fluoxetine, venlafaxine and desipramine in most assays.
Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
  • D. Wong, F. Bymaster
  • Psychology, Biology
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 2002
TLDR
Comparative trials of dual uptake inhibitors against the other agents are needed to establish whether the dual uptake inhibitor show improvement in efficacy, rate of responders, antidepressive effects and/or remission.
The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
TLDR
Duloxetine appears to have better response rates and remission from depressive symptoms, perhaps due to its ability to treat a wider range of symptoms.
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
TLDR
In conclusion, S33005 interacts potently with SERTs and, less markedly, with NETs and enhances extracellular levels of 5-HT and NE throughout corticolimbic structures and selectively elevates dialysis levels of DA in frontal cortex versus subcortical regions.
Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats
Pharmacodynamic and toxicological evaluation of duloxetine
TLDR
Duloxetine exerted an excellent antidepressant effect, and the acute toxicity response was mainly related to CNS, with potential side effect on the gastrointestinal tract.
SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants
Abstract The class of serotonin and norepinephrine reuptake inhibitors (SNRIs) now comprises three medications: venlafaxine, milnacipran, and duloxetine. These drugs block the reuptake of both…
Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test
TLDR
Depletion of serotonin prevented the behavioral effects of the selective serotonin reuptake inhibitor fluoxetine in the rat FST, and depletion of serotonin had no impact on the behavior effects induced by the selective norepinephrine reptake inhibitor, desipramine.
The neuropharmacology of serotonin and noradrenaline in depression
  • D. Nutt
  • Psychology, Biology
    International clinical psychopharmacology
  • 2002
TLDR
The use of central monoamine depletion studies has demonstrated that it is elevated synaptic monoamine levels themselves, rather than some downstream postsynaptic changes in, for example, receptor sensitivity, that are responsible for the therapeutic effect of antidepressant drugs.
...
1
2
3
4
5
...